Step therapy

Step therapy is the insurance rule that makes you try a cheaper medication before the plan will pay for a more expensive one. It is sometimes called fail-first, which is a more honest name: the plan wants documentation that the preferred drug did not work or was not tolerated before it approves the one your clinician actually chose.

In GLP-1 coverage it shows up in predictable patterns. A plan may require a trial of an older weight medication — phentermine, or a combination product — before a GLP-1. It may require semaglutide before tirzepatide, or a specific brand before its competitor, depending on which manufacturer holds the rebate contract that year. Those preferences change at renewal, which is why a drug covered in January can require a new step in the following plan year.

The rules almost always include an exceptions pathway, and that is the part worth knowing. Medicare Part D has a formal process for coverage determinations, exceptions and appeals, and commercial plans maintain their own. A documented contraindication, a previously failed trial, or a clinical reason the preferred drug is inappropriate can bypass a step — but only if it is written in the chart.

Two misunderstandings are common. First, people assume a past trial at a different insurer does not count; often it does, if records can be produced. Second, people assume “failed” means the drug did nothing — intolerable side effects count as failure too, and are frequently the stronger argument.

Before starting anything, ask your plan which GLP-1 is preferred this year, whether a step applies, and what documentation satisfies an exception. Bring records of any previous weight medication, including why you stopped. Our employer plan checker and coverage guide map out how the tiers work.